Repligen Corporation (RGEN) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, RGEN scores 64 out of 100, a letter grade of C, with the verdict "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars break down as follows. Fundamental cash engine scores 10 of 20, reflecting an ROIC of 2.3% and a FCF yield of 0.88%; this is the weakest pillar and signals that the business currently generates modest returns on capital relative to its valuation. Whale 13F flow scores 17 of 20, indicating institutional accumulation and options positioning as a relative strength. Insider conviction scores 8 of 20, based on SEC Form 4 and Congressional PTR cluster flow, which points to limited insider-driven confidence signals. Macro regime fit scores 11 of 20, with a beta of 1.04 and sector sensitivity as the noted drivers. Forensic balance sheet scores 18 of 20, supported by an Altman Z of 9.31, a Piotroski F of 8/9, and a debt-to-equity of 0.17, making it the strongest pillar.

For a prospective investor evaluating the stock today, the rating describes a company with a clean balance sheet and institutional support but thin current cash returns and a valuation that the source data shows at an EV/EBITDA of 95. The upside case rests on margin and return-on-capital improvement, since operating margin is only 1.8%. The valuation tradeoff is that the stock is priced well ahead of current cash generation. The rating frames this as balanced risk-reward rather than a clear buy or sell signal.

Repligen Corporation (RGEN) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the company profile, it carries a market capitalization of $10.7B. Gross margin of 88.2% is reported in the market data. Not available in source data for detailed product lines, customer base, or revenue model beyond sector and industry classification.

Reported operating margin is 1.8% and net margin is 1.6%, against an 88.2% gross margin, per the market data. ROIC is 2.3%. The Altman Z-Score of 9.31 and Piotroski F-Score of 8/9 appear in the Roarable RQD rating, and debt-to-equity is 0.17. Revenue is reported as $0.0M in each period, which is not reconciled in the source data.

Per the recent news feed, the most substantive item is a headline reporting that Repligen Completes BioLife Acquisition to Expand Cell Therapies. Other items reference a 2026 Q3 earnings call presentation dated 2026-10-27, a Q3 earnings preview, and a report that the CEO sold shares at $190 and $178.75 under a preset trading plan. All items are flagged YELLOW with impact label MARKET WIRE. Price was reported up 2.14% on volume of 890,335. Risk watch items include the thin operating margin and the EV/EBITDA of 95. The Butterfly supply-chain graph reports no links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and 2nd-order bottlenecks are not available in source data. The only sector context provided is the Health Care sector classification and the beta of 1.04.

• What is the revenue figure? Reported revenue is $0.0M across all periods, which conflicts with the reported operating and net income figures.
• What are the P/E and EPS figures on a trailing and forward basis?
• What drove the 2024 net loss and operating loss, and how did the company return to profit in 2025?
• How will the BioLife acquisition affect margins, ROIC, and the debt load?
• What is the FY 2023 cash balance, which is missing from the source data?